Existing users please login

Forgot Password

    Home / Markets / Industries / Health Care

    Tuesday, November 24, 2009

    Shire Applies For Euro Approval Of Gaucher Drug

    | Respond to Editor | Print

     
    By Val Brickates Kennedy
    MarketWatch Pulse
       

      BOSTON -- Shire plc said early Tuesday that it has applied for European marketing approval of its drug velaglucerase alfa, a treatment for the rare genetic disorder Gaucher disease. The product is also awaiting approval in the U.S. If approved, the drug would compete against Genzyme Corp.'s flagship product Cerezyme. A third company, Israel's Protalix BioTherapeutics is also finishing development on a drug to treat the disorder.

      Copyright © 2009 MarketWatch, Inc.

      Fox Business Video


      Last 5 Stocks

      • Ticker
      • Company
      • Price
      • Change
       

      Personal Finance - Investing - Financial News - Business News - Stock Market Quotes & News - Small Business

      Advertise with us | Jobs at FOX Business Network | Internships at FBN

      Terms of use. Privacy Statement. For FOXBusiness.com technical issues write to foxbusinessonline@foxbusiness.com; for all other feedback, write to feedback@foxbusiness.com.

      Quotes delayed at least 15 minutes. Market Data provided by Interactive Data (Terms & Conditions). Powered and implemented by Interactive Data Managed Solutions. Company fundamental data provided by Morningstar. Earnings estimates data provided by Zacks. Mutual fund data provided by Lipper. Economic data provided by Econoday. Dow Jones & Company Terms & Conditions.

      This material may not be published, broadcast, rewritten, or redistributed. ©2010 FOX News Network, LLC. All rights reserved.